119 related articles for article (PubMed ID: 37524857)
1. MAT as a promising therapeutic strategy against triple-negative breast cancer via inhibiting PI3K/AKT pathway.
Wei S; Zhang Y; Ma X; Yao Y; Zhou Q; Zhang W; Zhou C; Zhuang J
Sci Rep; 2023 Jul; 13(1):12351. PubMed ID: 37524857
[TBL] [Abstract][Full Text] [Related]
2. Rujifang inhibits triple-negative breast cancer growth via the PI3K/AKT pathway.
Jia W; Lin X; Chen X; Li H; Zhang X; Zhang Y; Chen Y; Wang B; Chen X; Chen J; Tian H
J Ethnopharmacol; 2024 Jun; 327():118011. PubMed ID: 38467320
[TBL] [Abstract][Full Text] [Related]
3. Osteopontin promotes tumor growth and metastasis and GPX4-mediated anti-lipid peroxidation in triple-negative breast cancer by activating the PI3k/Akt/mTOR pathway.
Guo M; Liu M; Li W; Wang C; Zhang L; Zhang H
J Cancer Res Clin Oncol; 2024 Mar; 150(3):155. PubMed ID: 38526702
[TBL] [Abstract][Full Text] [Related]
4. Network pharmacology and in vitro experiments reveal sophoridine-induced apoptosis and G
Su Y; Chen L; Yang J
Chem Biol Drug Des; 2024 Feb; 103(2):e14476. PubMed ID: 38346772
[TBL] [Abstract][Full Text] [Related]
5. Synergistic anti-proliferative activity of JQ1 and GSK2801 in triple-negative breast cancer.
Yellapu NK; Ly T; Sardiu ME; Pei D; Welch DR; Thompson JA; Koestler DC
BMC Cancer; 2022 Jun; 22(1):627. PubMed ID: 35672711
[TBL] [Abstract][Full Text] [Related]
6. Linc00707 regulates autophagy and promotes the progression of triple negative breast cancer by activation of PI3K/AKT/mTOR pathway.
Li H; Liu Q; Hu Y; Yin C; Zhang Y; Gao P
Cell Death Discov; 2024 Mar; 10(1):138. PubMed ID: 38485945
[TBL] [Abstract][Full Text] [Related]
7. Benzo[
Guerra FS; Dias FRF; Cunha AC; Fernandes PD
Molecules; 2021 Jul; 26(15):. PubMed ID: 34361566
[TBL] [Abstract][Full Text] [Related]
8. G-4 inhibits triple negative breast cancer by inducing cell apoptosis and promoting LCN2-dependent ferroptosis.
Sun G; Wang J; Liu F; Zhao C; Cui S; Wang Z; Liu Z; Zhang Q; Xiang C; Zhang Y; Galons H; Yu P; Teng Y
Biochem Pharmacol; 2024 Apr; 222():116077. PubMed ID: 38395264
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and biological evaluation of novel 1,3,4,9-tetrahydropyrano[3,4-b]indoles as potential treatment of triple negative breast cancer by suppressing PI3K/AKT/mTOR pathway.
Qin J; Sun X; Ma Y; Cheng Y; Ma Q; Jing W; Qu S; Liu L
Bioorg Med Chem; 2022 Feb; 55():116594. PubMed ID: 34990979
[TBL] [Abstract][Full Text] [Related]
10. Brucea javanica derived exosome-like nanovesicles deliver miRNAs for cancer therapy.
Yan G; Xiao Q; Zhao J; Chen H; Xu Y; Tan M; Peng L
J Control Release; 2024 Mar; 367():425-440. PubMed ID: 38295998
[TBL] [Abstract][Full Text] [Related]
11. Discovery of a Pimaradiene that Decreases Viability of MDA-MB-468 Cells Through Inhibition of EGFR Signaling Pathway.
Wang N; Qin L; Liu Z; Cao J; Huang J; Ma L; Huang G
Chem Biodivers; 2024 Apr; 21(4):e202400288. PubMed ID: 38415947
[TBL] [Abstract][Full Text] [Related]
12. Taurine Inhibits Lung Metastasis in Triple-Negative Breast Cancer by Modulating Macrophage Polarization Through PTEN-PI3K/Akt/mTOR Pathway.
Lin Y; Huang Y; Zheng Y; Chen W; Zhang Y; Yang Y; Huang W
J Immunother; 2024 Apr; ():. PubMed ID: 38630910
[TBL] [Abstract][Full Text] [Related]
13. Functionalized siRNA-chitosan nanoformulations promote triple-negative breast cancer cell death via blocking the miRNA-21/AKT/ERK signaling axis: in-silico and in vitro studies.
Abdulmalek SA; Saleh AM; Shahin YR; El Azab EF
Naunyn Schmiedebergs Arch Pharmacol; 2024 Apr; ():. PubMed ID: 38592437
[TBL] [Abstract][Full Text] [Related]
14. DDX58 deficiency leads to triple negative breast cancer chemotherapy resistance by inhibiting Type I IFN-mediated signalling apoptosis.
Cao S; Long X; Xiao L; Zhang P; Shen M; Chen F; Bao C; Zhong X; Luo T; Ye F
Front Oncol; 2024; 14():1356778. PubMed ID: 38549944
[TBL] [Abstract][Full Text] [Related]
15. Scutellaria barbata D.Don extract regulates Ezrin-mediated triple negative breast cancer progress via suppressing the RhoA /ROCK1 signaling.
Niu J; Hu J; Wang Z
Toxicol Res (Camb); 2024 Apr; 13(2):tfae033. PubMed ID: 38525246
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological Mechanism of Mume Fructus in the Treatment of Triple-Negative Breast Cancer Based on Network Pharmacology.
Yin L; Qi Y; Jiang Y
Appl Biochem Biotechnol; 2024 Apr; ():. PubMed ID: 38668843
[TBL] [Abstract][Full Text] [Related]
17. Antineoplastic effect of compounds C14 and P8 on TNBC and radioresistant TNBC cells by stabilizing the K-Ras4B
Carrión-Estrada DA; Aguilar-Rojas A; Huerta-Yepez S; Montecillo-Aguado M; Bello M; Rojo-Domínguez A; Arechaga-Ocampo E; Briseño-Díaz P; Meraz-Ríos MA; Thompson-Bonilla MDR; Hernández-Rivas R; Vargas M
Front Oncol; 2024; 14():1341766. PubMed ID: 38571493
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of TNBC Cell Growth by Paroxetine: Induction of Apoptosis and Blockage of Autophagy Flux.
Huang Q; Wu M; Pu Y; Zhou J; Zhang Y; Li R; Xia Y; Zhang Y; Ma Y
Cancers (Basel); 2024 Feb; 16(5):. PubMed ID: 38473249
[TBL] [Abstract][Full Text] [Related]
19. Insights into Mechanisms and Promising Triple Negative Breast Cancer Therapeutic Potential for a Water-Soluble Ruthenium Compound.
Nayeem N; Sauma S; Ahad A; Rameau R; Kebadze S; Bazett M; Park BJ; Casaccia P; Prabha S; Hubbard K; Contel M
ACS Pharmacol Transl Sci; 2024 May; 7(5):1364-1376. PubMed ID: 38751641
[TBL] [Abstract][Full Text] [Related]
20. Erianin inhibits the progression of triple-negative breast cancer by suppressing SRC-mediated cholesterol metabolism.
Li M; Kang S; Deng X; Li H; Zhao Y; Tang W; Sheng M
Cancer Cell Int; 2024 May; 24(1):166. PubMed ID: 38734640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
